Thrombosis Prevention In Heparin Induced Thrombocytopenia — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for thrombosis prevention in heparin induced thrombocytopenia. 2 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
2
Active US patents
80/100
Avg vulnerability
—
Annual revenue covered

Originators in Thrombosis Prevention In Heparin Induced Thrombocytopenia

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Hikma Pharm Co Ltd 2 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating thrombosis prevention in heparin induced thrombocytopenia. Each bar = one year. Y-axis scaled to peak year (2 patents).

2
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Argatroban
ARGATROBAN
 Hikma Pharm Co Ltd 2 80 — 2027-09-26

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7687516 Argatroban method of use 80 2027-09-26
7589106 Argatroban method of use 80 2027-09-26

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7687516 Argatroban method of use 80 2027-09-26
7589106 Argatroban method of use 80 2027-09-26

Related